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Background: Magnetic nanoparticles show great promise for use as tools in a wide variety 
of biomedical applications. The purpose of this study was to investigate the potential effects of 
methacrylamido-folic acid (Ma-Fol)-modified magnetic nanoparticles on 5RP7 (H-ras-transformed 
rat embryonic fibroblasts) and NIH/3T3 (normal mouse embryonic fibroblasts).
Methods: The cytotoxicity and viability of 5RP7 and NIH/3T3 cells were detected. The per-
centage of cells undergoing apoptosis was analyzed by flow cytometry using Annexin V-fluo-
rescein isothiocyanate staining. Nanoparticle internalization into 5RP7 and NIH/3T3 cells was 
visualized by transmission electron microscopy.
Conclusion: In this study, folic acid coupled to the surface of iron oxide for selective binding 
to cancer cells and immobilized the surfaces of magnetic nanoparticles. This complex improves 
cell internalization and targeting of cancer cells. We detected increased apoptosis using flow 
cytometry and transmission electron microscopy.
Results: Folic acid modification of magnetic nanoparticles could be used to facilitate uptake 
to specific cancer cells for cancer therapy and diagnosis. Our results showed that the uptake of 
folic-acid modified nanoparticles by 5RP7 cancer cells was also much higher than that of 3T3 
cells. This modification can be used for successful targeting of cancer cells expressing the folate 
receptor.
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Introduction
Cancer affects millions of people in all age groups. Many conventional cancer 
chemotherapies are ineffective because of an inability to reach the tumor site in 
effective concentrations.1 There is little doubt that nanoparticles offer new oppor-
tunities in many fields.2 Nanotechnology is expected to revolutionize medicine. 
Nanostructures can play a major role in medicine, especially in cancer diagnosis 
and therapy.3
Magnetic nanoparticles have been investigated for various biomedical applications, 
eg, Fe3O4 nanoparticles, and prospected in diagnostic research for magnetic resonance 
imaging and application of nanotechnologies in medicine.4 Magnetic nanoparticles 
could enhance therapeutic effects and reduce side effects of drugs when used in com-
bination with conventional cancer treatment.5 The combination of Fe3O4 magnetic 
nanoparticles with different chemotherapeutics may provide new strategies in the 
treatment of specific cancer cells.6
Moreover, Fe3O4 nanoparticles are the only magnetic nanomaterials approved for 
clinical use by the US Food and Drug Administration, and the preparation method International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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is relatively simple.7 We aimed to determine whether the 
anticancer effects of methacrylamido-folic acid (Ma-Fol) 
would have improved anticancer activity if incorporated 
into magnetic nanoparticles. We demonstrated that mag-
netic Fe3O4 nanoparticles coupled with folic acid can inhibit 
tumor proliferation and induce apoptosis of cancer cells in 
a dose- and time-dependent manner.
Folic acid is a water-soluble vitamin. It has been used 
for targeting drugs to cancer cells. The folate receptor is 
significantly overexpressed on the surface of human cancer 
cells.8,9 Folate receptor-mediated drug delivery is based on 
conjugation with folic acid, which is internalized by folate 
receptor-mediated endocytosis. Folic acid has been 
immobilized on superparamagnetic particles,10 polymer 
nanoparticles,11 and incorporated into dendrimer-based 
therapeutic nanodevices12 for selective targeting of tumor 
cells. Folate receptors exhibit limited expression on healthy 
cells, but are often present in large numbers on cancer 
cells.13 Folic acid receptors are overexpressed by epithelial 
cancers in the ovary, mammary gland, colon, lung, prostate, 
nose, throat, and brain,14 so represent an important target 
for tumor-specific delivery of anticancer drugs.
Cell death can be categorized as apoptosis and as 
necrosis. Apoptosis, or programmed cell death, is an active 
process characterized by cytoplasmic shrinkage, chromatin 
condensation, nuclear fragmentation, and activation of 
caspases.13 In addition, phosphatidylserine is exposed on the 
external surface of the cell in the early phase of apoptosis, 
and this exposure precedes membrane damage and DNA 
fragmentation.15 On the other hand, necrosis is passive, and 
is characterized by cell swelling, rupture of the plasma 
membrane, and cell lysis, with leakage of cytoplasmic com-
ponents, such as lactate dehydrogenase.13 In the present study, 
folic acid was coupled on the surface of Fe3O4 for selective 
binding to cancer cells and immobilized on the surfaces of 
magnetic nanoparticles, to disperse particles and improve 
their cell internalization and target cancer cells, respectively. 
Further, the apoptotic effects of Ma-Fol-modified Fe3O4 
nanoparticles were determined in a 5RP7 (H-ras-transformed 
rat embryonic fibroblasts) and in a NIH/3T3 control cell line 
(normal mouse embryonic fibroblasts) by flow cytometry 
and transmission electron microscopy (TEM).
Nanoparticles are generally internalized into cells via 
fluid-phase endocytosis,16,17 receptor-mediated endocytosis, 
or phagocytosis. One strategy to realize efficient and specific 
cellular uptake of nanoparticles is to modify the nanoparticle 
surface with a ligand that is efficiently taken up by target 
cells via receptor-mediated endocytosis.18
The objective of this research was to assess the potential 
effects of Fe3O4 magnetic nanoparticles modified with 
Ma-Fol on 5RP7 cancer cells and NIH/3T3 cells.
Materials and methods
Synthesis and characterization  
of magnetic nanoparticles with Ma-Fol
Folic acid (1 equivalent) was dissolved in 50 mL of water. 
pH was set to 9–10 by addition of 1 M NaOH solution to 
obtain anionic folate in solution. A solution of methacryloyl 
benzotriazole19,20 in dioxane (15 mL) was added to the folate 
solution. This mixture was stirred for 30 minutes at room 
temperature. Completion of the reaction was monitored 
by  thin  layer  chromatography,  which  showed  free 
1H-benzotriazole spot. Dioxane was evaporated under 
vacuum. Reaction mixture was extracted with ethyl acetate 
(3 × 20 mL) to remove 1H-benzotriazole. Water layers were 
acidified with 0.1 M HCl solution to adjust to pH 5–6. 
Water was evaporated under vacuum to get Ma-Fol as yellow 
microcrystals in an 85% yield.
1H nuclear magnetic resonance (NMR, 500 mHz, 
DMSO-d6) δ  was  as  follows:  8.56  (s,  1  H),  7.59 
(d,  3JHH = 8.80 Hz, 1 H), 6.65 (d,  3JHH = 8.80 Hz, 1 H), 
5.56–5.53 (m, 1 H), 5.03–5.00 (m, 1 H), 4.45 (s, 2 H), 4.05 
(dd, 3 JHH = 5.05, 7.0 Hz, 1 H), 2.25–2.15 (m, 2 H), 2.10–1.90 
(m, 2 H), 1.96 (s, 3 H) ppm. 13C NMR (125 mHz, DMSO-d6) 
δ: 174.0, 173.9, 167.2, 167, 164.9, 164.2, 153.1, 151.9, 151.4, 
149.4, 141.4, 129.5, 126.7, 118.7, 112.8, 110.6, 53.9, 45.7, 
30.1, 27.9, 18.7 ppm.
Superparamagnetic iron oxides (size 20–50 nm), were 
obtained from Sigma-Aldrich Chemical Co (St. Louis, MO). 
The surfaces of 0.1 g iron nanoparticles were modified in 
2.5 mL toluene, adding 0.5 mL trimethoxysilyl propyl 
methacrylate. These silylated superparamagnetic iron oxide 
nanoparticles were mixed with a 5 mg/mL molality of 1 mL 
Ma-Fol in 1 mL dimethyl sulfoxide (Sigma-Aldrich 
Chemical Co). The chemicals were diluted in dimethyl 
sulfoxide before addition to the cultures. The final concentra-
tion of dimethyl sulfoxide was 0.1%.
cell culture
5RP7 (H-ras-transformed rat embryonic fibroblasts) and 
NIH/3T3 (a control cell line of normal mouse embryonic 
fibroblasts) were used in these experiments. Frozen stock 
vials of the cells were thawed and used. Cells were rou-
tinely cultured at 37°C in a humidified atmosphere with 
5% CO2 in 25 cm2 flasks containing 5 mL of Dulbecco’s 
modified Eagle’s medium, supplemented with 10% fetal International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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bovine serum, 2 mM L-glutamine, 50 IU/mL penicillin, 
and 50 mg/mL streptomycin. The medium was changed 
every third day. For subculture, the cells were washed 
twice with phosphate-buffered saline and incubated with 
trypsin-ethylenediamine tetra-acetic acid solution 
(0.25% trypsin, 1 mM ethylenediamine tetra-acetic acid) 
for 2 minutes at 37°C to detach the cells, and the complete 
media were then added into the flask at room temperature 
to inhibit the effect of trypsin. The cells were washed twice 
by centrifugation and resuspended in the complete media 
for reseeding and growing in new culture flasks. 
Cell viability was determined through staining with trypan 
blue, and cells were counted using a hemocytometer.
To study the cellular uptake of the nanoparticles by 
flow cytometry and TEM, Ma-Fol-modified magnetic 
nanoparticles were added to the cell culture media at con-
centrations of 2.5 µg/mL, 4.5 µg/mL, and 9 µg/mL. 
The cells were cultured and then reseeded with the nano-
particle-dispersed culture media. After 24 and 48 hours of 
incubation at 37°C, the cells were washed twice with 
phosphate-buffered saline, detached using trypsin-ethyl-
enediamine tetra-acetic acid solution, and resuspended in 
culture media. In control cultures, the cells were placed in 
5 mL of medium without magnetic nanoparticles at the 
same cell density.
Flow cytometry
Annexin V-fluorescein isothiocyanate (FITC) is a sensitive 
probe for identifying apoptotic cells. It binds to negatively 
charged phospholipid surfaces with a higher specificity for 
phosphatidylserine, a membrane phospholipid, than for 
most other phospholipids.21 In apoptotic cells, phosphati-
dylserine is translocated from the inner leaflet of the 
plasma membrane to the outer leaflet, thereby exposing 
phosphatidylserine to the external environment.22 
A FACSAria (BD Corporation, Bedford, MA) flow 
cytometer was used for analysis of the cells. A recent report 
suggested that the uptake of Fe3O4 nanoparticles by cells 
could be quantitatively measured using flow cytometric 
light scatter.6 Annexin V binding was performed using an 
AnnexinV-FITC kit (BD Corporation) as described by the 
manufacturer. Cells were washed twice with cold 
phosphate-buffered saline and were then resuspended in 
1× binding buffer at a concentration of 1 × 106 cells/mL, 
after which 100 µL of solution (1 × 105 cells) was trans-
ferred to a 5 mL culture tube. Annexın V-FITC 5 µL and 
propidium iodide 5 µL were added, and the cells were then 
incubated for 15 minutes at room temperature in the dark, 
after which 400 µL of 1× binding buffer was added to each 
tube and analyzed in the FACSAria.
Transmission electron microscopic 
analysis
Uptake of nanoparticles modified with folic acid by NIH/3T3 
and 5RP7 cancer cells, as well as nanoparticle size and 
morphology, were determined using a TEM (FEI Tecnai 
BioTWIN). Samples for TEM measurement were prepared 
by dispersing the particles in dimethyl sulfoxide. Cells were 
deposited on Formvar-coated 200–300 mesh copper grids and 
dried, fixed with 2.5% glutaraldehyde in 0.1 M phosphate 
buffer (pH 7.4), and left in phosphate-buffered saline 
overnight at 4°C. After being embedded in agar and after 
fixation in 2% osmium tetroxide, the cells were dehydrated 
in graded ethanol, ie, 70, 90, 96, and 100%. The cells were 
then embedded in EPON 812 epoxy. They were thin-sectioned 
using a diamond knife to a maximum thickness of 100 nm. 
The sections were stained with lead citrate and uranyl 
acetate.
Results and discussion
A logical method to promote internalization of nanoparticles 
is to modify their surface with a ligand such as folic acid 
which can be efficiently taken up by cells through receptor-
mediated endocytosis.23 Folic acid binds to the folate recep-
tors at cell surfaces with very high affinity and is internalized 
by receptor-mediated endocytosis.24,26 More importantly, folic 
acid is stable, poorly immunogenic, and has the ability to 
target cancer cells preferentially because the folate receptor 
is frequently overexpressed on the surface of cancer cells.
Flow cytometry is a process whereby physical or 
biochemical parameters of single biological cells or particles 
are measured as the cells move through a fluidic channel.27 
The Annexin V binding assay provides a very specific, rapid, 
and reliable technique to detect apoptosis by flow cytometry 
or by fluorescence microscopy.28,29 FITC is a very useful 
fluorescent moiety that can be used to label essentially any 
protein. FITC-conjugated Annexin V is used to detect apop-
totic cells in a diverse range of cell types and in response to 
many different proapoptotic stimuli.28,29
Iron nanoparticles were successfully modified with Ma-
Fol as described in the Methods section. The nanoparticles 
appeared to be spherical, and diameters were 24–30 nm. 
Ma-Fol was used to target preferentially cancer cells with 
folate receptors expressed on their surfaces, and to facilitate 
the nanoparticles to transit across the cell membrane. 
Annexin V-FITC allows detection of cell surface changes International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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that occur early during apoptosis, because Annexin V binds 
to phosphatidylserine which becomes exposed on the outer 
surface of the plasma membranes by flipping from the inner 
side of the membrane.22,30,31 Exposure of phosphatidylserine 
during apoptosis precedes nuclear changes. This change in 
membrane surface is important for macrophages to recog-
nize cells undergoing apoptosis.30,32 Annexin V , an antico-
agulant protein, binds to phosphatidylserine with high 
affinity. Thus, by staining cells with Annexin V-FITC and 
additionally with DNA-specific fluorochrome, eg, propidium 
iodide, it is possible to identify live cells, early apoptotic 
cells, as well as late apoptotic and necrotic cells, by flow 
cytometry.22,33 Subsequently, Annexin V-FITC binds to cells 
expressing phosphatidylserine, an early marker of apoptosis 
on the cell surface. Target cells are gated upon as propidium 
iodide-negative and quantified with respect to their Annexin 
V positivity. The shift from Annexin Vneg to Annexin Vhigh is 
a discrete event, such that all target cells fall within discern-
ible populations with respect to Annexin V. Dead or dying 
cells are then stained with Annexin V-FITC.34 Annexin V 
has been used to detect apoptotic cells in a wide variety of 
cell types. Externalization of phosphatidylserine has been 
demonstrated in plasma membrane permeability changes, 
as measured by propidium iodide uptake and Annexin V 
binding, and precedes the morphological features of apop-
tosis as assessed by flow cytometric analysis of cell 
shrinkage.29,34 The sensitivity and early kinetics of Annexin 
V binding make it an ideal marker for cell death in a flow 
cytometric assay.34 Analysis of Annexin V/propidium iodide-
stained cells by flow cytometry allows quantitation of the 
fraction of cells that are Annexin V-negative and propidium 
iodide-negative (double negative), Annexin V-positive and 
propidium iodide-negative (single positive), or Annexin 
V-positive and propidium iodide-positive (double positive).28 
A number of detectors are aimed at the point where the 
stream passes through the light beam, ie, one in line with 
the light beam (forward scatter) and several perpendicular 
to it (side scatter) and one or more fluorescent detectors. 
Forward scatter correlates with the cell volume, and side 
scatter depends on the inner complexity of the particle (ie, 
shape of the nucleus, amount and type of cytoplasmic gran-
ules, or membrane roughness).35 Data analysis was per-
formed with Diva Software (BD FACS Diva software 6.0; 
BD Corporation, Bedford, MA). Analyses were conducted 
on 10,000 cells in each case. Apoptosis was quantitatively 
confirmed by analyzing the percentage of early apoptotic 
cells using Annexin V-FITC/propidium iodide double stain-
ing. A marker of early apoptosis, measured by Annexin-V, 
is phosphatidylserine, which is released as a result of 
redistribution of the plasma membrane of the cells.22 Three 
main populations of cells were distributed in dot-plots for 
viable cells Q3 (Annexin V-negative/propidium iodide-
negative), early apoptotic cells Q4 (Annexin V-positive/
propidium iodide-negative), and late apoptotic and necrotic 
cells Q2 (Annexin V-positive/propidium iodide-positive). 
The cytotoxicity of folic acid-modified nanoparticles was 
determined by exposing normal cells and cancer cells to 
various concentrations in Dulbecco’s Modified Eagle’s 
Medium for 24 and 48 hours. Nanoparticles were dispersed 
in dimethyl sulfoxide. The final concentration of dimethyl 
sulfoxide was 0.1%. The results and respective percentages 
of cells in apoptotic regions for both NIH/3T3 and 5RP7 cells 
are given in Figures 1 and 2. The results indicate that there 
was no significant loss of cell survival if the incubated con-
centration of Ma-Fol-modified nanoparticles was 4.5 µg/mL 
or below in cancer cells. As the concentration increased to 
9 µg/mL, the rate of viability was close to that of normal 
cells. These results confirm that the cells are saturated with 
Ma-Fol-modified nanoparticles at a concentration of 4.5 µg/
mL. Up to this concentration, the magnetic nanoparticles 
were aggregated and had difficulty penetrating into the 
cancer cells. Figure 2 shows cell death due to the Ma-Fol-
modified magnetic nanoparticles at 4.5 µg/mL for 24 hours 
in cancer cells. When cells were exposed to a nanoparticle 
concentration of 4.5 µg/mL for 24 hours, cell survival 
decreased to 83%. When incubation time was extended to 
48 hours, cell viability decreased further to 80%. As shown 
in Figure 2, folic acid-modified nanoparticles caused worse 
damage to cancer cells than to normal cells. The population 
of Annexin V-positive live cells increased in a time-depen-
dent manner, and most (12.9%) of the cells became Annexin 
V-positive at 48 hours (Figure 2). When cancer cells were 
incubated with modified magnetic Ma-Fol nanoparticles for 
48 hours (9 µg/mL), the population of Annexin V-positive 
live cells was found to be 7.3% (Figures 2A and 2B). Cells 
in the late stages of apoptosis are located in the bottom right 
quadrant of the dot-plot as double positive Annexin V-FITC- 
and propidium iodide-binding cells because, at this stage, 
the cell membranes are damaged and propidium iodide has 
penetrated into the cell. In the later stages of apoptosis, 
propidium iodide enters the cell, leading to a double positive 
population.28 Cells undergoing necrotic cell death also stain 
as double positive for Annexin V and propidium iodide, as 
discussed earlier.
Flow cytometry by this double staining method enables 
clear detection of three populations of cells (viable, apoptotic, International Journal of Nanomedicine 2011:6
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Figure 1 Flow cytometric analysis of NIH/3T3 cells by double labeling with Annexin V-fluorescein isothiocyanate and propidium iodide. Unfixed cells from control 
and treated groups were labeled with Annexin V-fluorescein isothiocyanate and propidium iodide and then fixed and analyzed on a flow cytometer. Dual parameter 
dot-plot of propidium iodide-phycoerytrin (x-axis), Annexin V-fluorescein isothiocyanate fluorescence (y-axis) showing logarithmic intensity. Quadrants are viable 
cells Q3 (Annexin V-negative/propidium iodide-negative), early apoptotic cells Q4 (Annexin V-positive/propidium iodide-negative), and late apoptotic and necrotic cells Q2 
(Annexin V-positive/propidium iodide-positive). Percentage of apoptotic cells are A) control cells, 1.5%; B) dimethyl sulfoxide control cells, 1.6%; C) Ma-Fol-modified 
magnetic nanoparticles, 2.5 µg/mL, 24 hours, 2.7%; D) Ma-Fol-modified magnetic nanoparticles 2.5 µg/mL, 48 hours, 2.8%; F) Ma-Fol-modified magnetic nanoparticles   
4.5 µg/mL, 24 hours, 4.3%; G) Ma-Fol-modified magnetite nanoparticles 4.5 µg/mL, 48 hours, 4.7%; H) Ma-Fol-modified magnetic nanoparticles 9 µg/mL, 24 hours, 2.9%;   
I) Ma-Fol-modified magnetic nanoparticles 9 µg/mL, 48 hours, 3.1%.
Abbreviation: Ma-Fol, methacrylamido-folic acid.
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Figure 2 Flow cytometric analysis of 5RP7 (H-ras-transformed fibroblasts) by double labeling with Annexin V-fluorescein isothiocyanate and propidium iodide. Control 
cells were labeled with Annexin V-fluorescein isothiocyanate and propidium iodide, and then fixed and analyzed on a flow cytometer. Quadrants are viable cells Q3 
(Annexin V-negative/propidium iodide-negative), early apoptotic cells Q4 (Annexin V-positive/propidium iodide-negative) and late apoptotic and necrotic cells Q2 (Annexin 
V-positive/propidium iodide-positive). Percentage of apoptotic cells are A) control cells, 1.1%; B) dimethyl sulfoxide control cells, 1.2%; C) Ma-Fol-modified magnetic 
nanoparticles 2.5 µg/mL, 24 hours 7.2%; D) Ma-Fol modified magnetic nanoparticles 2.5 µg/mL, 48 hours, 8.1%; E) Ma-Fol-modified magnetic nanoparticles 4.5 µg/mL, 
24 hours, 10.5%; F) Ma-Fol-modified magnetic nanoparticles 4.5 µg/mL, 48 hours, 12.9 %.
Abbreviation: Ma-Fol, methacrylamido-folic acid.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
481
Methacrylamido-folic acid nanoparticles
and necrotic). Thus, the early apoptotic cells bind only to 
Annexin-V FITC, and late apoptotic cells to both Annexin 
V-FITC and propidium iodide, and viable cells do not take 
up any of the dye. The Annexin V-FITC/propidium iodide 
population was considered to reflect normal healthy 
cells, whereas Annexin V-FITC-positive/propidium 
iodide-negative cells were taken to show early apoptosis. 
Annexin V-FITC -positive/propidium iodide-negative cells 
were in late apoptosis or necrosis.35
Our flow cytometric analysis has shown that48 hours 
of treatment with Ma-Fol-modified magnetic nano-
particles caused apoptosis in a 5RP7 cell line in a International Journal of Nanomedicine 2011:6
Figure  3  Transmission  electron  micrographs  of  Fe3O4  magnetic  nanoparticles. 
A) 160,000×; B) 105,000×.
Figure 4 Transmission electron micrographs of NIH/3T3 cell (16,500×) not treated 
with folic acid-modified magnetic nanoparticles.
Figure 5 Transmission electron micrographs of a Ih/3T3 cell. A) (6000×) treated 
with 4.5 µg/mL Ma-Fol-modified magnetic nanoparticles for 24 hours. B) (16,500×) 
treated with 4.5 µg/mL folic acid-modified magnetic nanoparticles for 48 hours. 
Abbreviation: Ma-Fol, methacrylamido-folic acid.
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concentration-dependent manner. Ma-Fol-modified mag-
netic nanoparticles at a dose of 4.5 µg/mL showed 12.9% 
cells in the apoptotic zone in the case of NIH/3T3 cells, 
and the same concentration produced apoptosis in 4.7% of 
cells in dot-plot analysis. Late apoptosis and necrosis 
increased steadily following the increase at a concentration 
of 4.5 µg/mL. Flow cytometric determination of cell cycle 
phase distribution has further confirmed that folic acid-
modified magnetic nanoparticles cause cell cycle deforma-
tion in a cancer cell line.
The results of this study confirm that cancer cells have 
more folate receptors, and that a 4.5 µg/mL concentration of 
folic acid-modified magnetic nanoparticles causes apoptosis 
in 5RP7 cells. The uptake of folic acid-modified nanoparti-
cles by cancer cells was also much higher than that of normal 
cells. This indicates that folic acid modification not only 
facilitates the nanoparticles to target specific cells, but also 
increases the yield of cell internalization. The interaction 
between folic acid and folate receptors expressed on the 
surface of cancer cells might have contributed to the 
improvement of nanoparticle uptake, based on receptor-
mediated endocytosis.37
The schemes for the modification of nanoparticles display 
TEM images (Figure 3) of Ma-Fol-modified with Fe3O4 
nanoparticles for this purpose, firstly, magnetic nanoparticles 
were imaged. These images indicate that all the Fe3O4 nano-
particles were in the nanosized range. The average particle 
size is about 30 nm. Figure 4 shows the TEM images of 
NIH/3T3 cells not treated with Ma-Fol-modified magnetic 
nanoparticles. Figure 5 shows the uptake of folic acid-mod-
ified nanoparticles into normal cells at 24 hours and 48 hours. 
The incubation of cells with folic acid-modified nanoparticles 
does not differ. The viability of normal cells after each incu-
bation time with the nanoparticles was close to that of control 
cells, and was in the 95%–96% range in flow cytometric 
analysis. The uptake of magnetic nanoparticles by cancerous 
rat 5RP7 fibroblasts is shown in Figure 7. After 48 hours of 
culture in media containing folic acid-modified nanoparticles, 
the morphology and viability of normal fibroblast cells con-
taining the modified nanoparticles were close to that of the 
control cells, suggesting biocompatibility of the nanoparticles. 
The TEM and flow cytometry results showed that folic 
acid-modified nanoparticles were internalized into both 
normal cells and cancer cells. The immobilization of folic 
acid on the nanoparticles was demonstrated by increasing the 
amount of nanoparticle uptake into cancer cells in comparison 
with normal cells. This suggests that the modification of 
magnetic nanoparticles with Ma-Fol could be used to resist 
nonspecific uptake and thus avoid their recognition by mac-
rophage cells, and simultaneously facilitate nanoparticle 
uptake to specific cancer cells for cancer therapy.
In flow cytometry results, the population of Annexin 
V-positive live cells in the cancer cell line increased in a 
time-dependent manner, and most (12.9%) of the cells 
became Annexin V-positive at 48 hours at a concentration 
of 4.5 µg/mL. The results indicate that there was no signifi-
cant loss of cell survival if the incubated concentration of 
Ma-Fol modified nanoparticles is 4.5 µg/mL or below in 
cancer cells. As the concentration increased to 9 µg/mL, the International Journal of Nanomedicine 2011:6
Figure 7 Transmission electron micrographs of 5RP7 cells; E) (8200×) (treated 
with 4.5 µg/mL folic acid-modified magnetic nanoparticles for 24 hours. F) (11,500×) 
treated with 4.5 µg/mL folic acid-modified magnetic nanoparticles for 48 hours 
leading to apoptotic blebbing.
Figure 6 Transmission electron micrographs of 5rP7 cells not treated with folic 
acid-modified magnetic nanoparticles. C) 4200×; D) 8200×.
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rate of viability was close to that of normal cells. These 
results confirm that cells saturated with folic acid-modified 
nanoparticles are detected in the 4.5 µg/mL concentration. 
Up to this concentration, magnetic nanoparticles were 
aggregated and had difficulty penetrating the cells. In TEM 
analysis, the concentration of 4.5 µg/mL was used to compare 
the cancer cells and normal cells at 24 and 48 hours.
In normal cells, organelles and cell structures were not 
affected by the presence of Ma-Fol-modified nanoparticles 
inside the cells (Figure 5). However, cancer cells treated with 
the 4.5 µg/mL concentration of Ma-Fol-modified nanoparticles 
underwent apoptosis. A representative picture of intracellular 
nanoconjugate uptake by NIH/3T3 cells during a 24-hour and 
48-hour treatment is shown in Figures 5 and 6. The amount 
of intracellular uptake of the nanoparticles can be seen in 
normal cells, whereas in the 5RP7 cell line the amount of the 
nanoconjugate was increased and cell modifications were 
damaged, Figure 7 clearly illustrates the internalization of 
Ma-Fol-modified nanoparticles and their localization near the 
nucleus and a great number of apoptotic particles. This picture 
shows clearly that nanoconjugate uptake was maximum, with 
5RP7 cells having maximum receptor expression, and hence 
the most intense color of the pellet, whereas the uptake gradu-
ally decreased with reduction in folate receptor expression 
and, accordingly, the intensity of the color of the pellet in the 
case of NIH/3T3. The picture confirms our hypothesis about 
the targeting efficacy of nanoconjugates containing folic acid, 
ie, that a positive correlation exists between maximum folate 
receptor expression and maximum uptake of nanoconjugates. 
The 5RP7 cells with 90% receptor expression showed 
maximum uptake, and the NIH/3T3 cells showed the least. 
This is further substantiated by TEM and flow cytometry 
analysis, confirming that folic acid-modified magnetic nano-
particles can be used as a targeting agent.
Ma-Fol-modified magnetic nanoparticles represent a 
potential novel delivery system for compounds with antican-
cer activity because the folate receptor is frequently overex-
pressed in cancer cells. Moreover, it may increase our ability 
to target drugs to tumor cells, protect the drug from in vivo 
degradation, and reduce drug toxicity. Further studies are in 
progress to test this new drug delivery system in vivo.
Conclusion
This study describes a simple method of attaching Ma-Fol 
to Fe3O4 nanoparticles. This modification containing folic 
acid can be used for successful targeting of tumor cells 
expressing the folate receptor. Future studies will focus on 
determining the stability and targeting efficacy of this modi-
fication in vivo. This study has important implications in 
cancer cell imaging, tumor ablation, and drug delivery 
because of its targeting efficacy. Furthermore, it needs to be 
investigated whether nanoparticles could cause long-term 
changes in systemic activity. However, the effect and usage 
of such combinations need to be investigated further in in 
vivo experiments.
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